期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

从肺动脉高压形成的病理生理机制看阿司匹林治疗的可能性 被引量：4

下载PDF
导出
摘要 肺动脉高压（pulmonary artefial hypertension，PAH）是一种危及生命的疾病，其特点是肺动脉压力和肺血管阻力进行性升高，最终导致右心衰竭和死亡。
作者 沈兰 沈节艳
机构地区 上海交通大学医学院附属仁济医院心内科
出处 《中国心血管杂志》 2010年第6期479-481,共3页 Chinese Journal of Cardiovascular Medicine
基金 上海市卫生局科研课题项目资助(2007103)
关键词 肺动脉高压形成 病理生理机制 阿司匹林 hypertension 治疗 肺血管阻力 肺动脉压力 右心衰竭
分类号 R543 [医药卫生—心血管疾病]
  • 相关文献

参考文献17

  • 1D'Alonzo GE,Barst RJ,Ayres SM,et al.Survival in patients with primary pulmonary hypertension.Results from a national prospective registry.Ann Intern Med,1991,115:343-349.
  • 2Tuder RM,Marecki JC,Richter A,et al.Pathology of pulmonary hypertension.Clin Chest Med,2007,28:23-42,vii.
  • 3Pidgeon GP,Tamosiuniene R,Chen G,et al.Intravascular thrombosis after hypoxia-induced pulmonary hypertersion:regulation by cyclooxygenase-2.Circulation,2004,110:2701-2707.
  • 4Badesch DB,Abman SH,Simonneau G,et al.Medical therapy for pulmonary arterial hypertension:updated ACCP evidencebased clinical practice guidelines.Chest,2007,131:1917-1928.
  • 5MacLean MR,Dempsie Y.Serotonin and pulmonary hypertension-from bench to bedside? Curr Opin Pharmacol,2009,9:281-286.
  • 6Shah SJ,Gomberg-Maitland M,Thenappan T,et al.Selective serotonin reuptake inhibitors and the incidence and outcome of pulmonary hypertension.Chest,2009,136:694-700.
  • 7Morecroft I,Loughlin L,Nilsen M,et al.Functional interactions between 5-hydroxytryptamine receptors and the serotonin transporter in pulmonary arteries.J Pharmacol Exp Ther,2005,313:539-548.
  • 8Rochefort GY,Lemaire MC,Eder V,et al.Dexfenfluramine does not worsen but moderates progression of chronic hypoxia-induced pulmonary hypertension.Eur J Pharmacol,2006,550:149-154.
  • 9Dempsie Y,Morecroft I,Welsh DJ,et al.Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.Circulation,2008,117:2928-2937.
  • 10Dempsie Y,MacLean MR.Pulmonary hypertension:therapeutic targets within the serotonin system.Br J Pharmacol,2008,155:455-462.

同被引文献72

  • 1薛超,李治安,何怡华,韩建成,谷孝艳,冯天鹰,刘琳.瓣环组织位移技术评价不同三尖瓣成形术后患者右心室收缩功能[J].中华医学超声杂志（电子版）,2011,8(11):2339-2344. 被引量：4
  • 2Kao PN, Faul JL. Emerging therapies for pulmonary hypertension striving for effecicacy and safety. J Am Coil Cardiol, 2003, 41 2126-2129.
  • 3Newman JH, Lane KB. Hypertension pulmonary vascular disease dawn of the age of prevention? Am J Respir Crit Care Med, 2000 162:2020-2021.
  • 4Hoeper MM, Markevych I, Spiekerkoetter E, et al. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J, 2005, 26:858-863.
  • 5Kinlay S. Potential vascular benefits of statins. Am J Med, 2005, 118 : $62-$67.
  • 6Sparrow CP, Burton CA, Hernandez M, et al. Simvastatin has anti- imflammation and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol, 2001, 21:115-121.
  • 7Nishimura T, Vsazar LT, Faul JL, et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation, 2003, 108: 1640-1645.
  • 8Murata T, Sato K, Hori M, et al. Decreased endothelial nitric- oxide synthase activity resulting from abnormal interaction between eNOS and its regulatory proteins in hypoxia-induced pulmonary hypertension. J Bio Chem, 2002, 277: 44085-44092.
  • 9Murata M, Kinoshita K, Hori M, et al. Statin protects endothelial nitric oxide synthase activity in hypoxia-induced pulmonary hypertension. Arterioseler Thromb Vase Biol, 2005, 25: 2335- 2342.
  • 10Shen L, Shen J, Pu J, He B. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Cell Bioehem Biophys, 2011, 61 : 23-31.

引证文献4

二级引证文献16

中国心血管杂志
2010年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部